Elucidating the role of artificial intelligence in drug development from the perspective of drug-target interactions.

IF 8.9 Journal of pharmaceutical analysis Pub Date : 2025-03-01 Epub Date: 2024-11-14 DOI:10.1016/j.jpha.2024.101144
Boyang Wang, Tingyu Zhang, Qingyuan Liu, Chayanis Sutcharitchan, Ziyi Zhou, Dingfan Zhang, Shao Li
{"title":"Elucidating the role of artificial intelligence in drug development from the perspective of drug-target interactions.","authors":"Boyang Wang, Tingyu Zhang, Qingyuan Liu, Chayanis Sutcharitchan, Ziyi Zhou, Dingfan Zhang, Shao Li","doi":"10.1016/j.jpha.2024.101144","DOIUrl":null,"url":null,"abstract":"<p><p>Drug development remains a critical issue in the field of biomedicine. With the rapid advancement of information technologies such as artificial intelligence (AI) and the advent of the big data era, AI-assisted drug development has become a new trend, particularly in predicting drug-target associations. To address the challenge of drug-target prediction, AI-driven models have emerged as powerful tools, offering innovative solutions by effectively extracting features from complex biological data, accurately modeling molecular interactions, and precisely predicting potential drug-target outcomes. Traditional machine learning (ML), network-based, and advanced deep learning architectures such as convolutional neural networks (CNNs), graph convolutional networks (GCNs), and transformers play a pivotal role. This review systematically compiles and evaluates AI algorithms for drug- and drug combination-target predictions, highlighting their theoretical frameworks, strengths, and limitations. CNNs effectively identify spatial patterns and molecular features critical for drug-target interactions. GCNs provide deep insights into molecular interactions via relational data, whereas transformers increase prediction accuracy by capturing complex dependencies within biological sequences. Network-based models offer a systematic perspective by integrating diverse data sources, and traditional ML efficiently handles large datasets to improve overall predictive accuracy. Collectively, these AI-driven methods are transforming drug-target predictions and advancing the development of personalized therapy. This review summarizes the application of AI in drug development, particularly in drug-target prediction, and offers recommendations on models and algorithms for researchers engaged in biomedical research. It also provides typical cases to better illustrate how AI can further accelerate development in the fields of biomedicine and drug discovery.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"15 3","pages":"101144"},"PeriodicalIF":8.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910364/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical analysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jpha.2024.101144","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Drug development remains a critical issue in the field of biomedicine. With the rapid advancement of information technologies such as artificial intelligence (AI) and the advent of the big data era, AI-assisted drug development has become a new trend, particularly in predicting drug-target associations. To address the challenge of drug-target prediction, AI-driven models have emerged as powerful tools, offering innovative solutions by effectively extracting features from complex biological data, accurately modeling molecular interactions, and precisely predicting potential drug-target outcomes. Traditional machine learning (ML), network-based, and advanced deep learning architectures such as convolutional neural networks (CNNs), graph convolutional networks (GCNs), and transformers play a pivotal role. This review systematically compiles and evaluates AI algorithms for drug- and drug combination-target predictions, highlighting their theoretical frameworks, strengths, and limitations. CNNs effectively identify spatial patterns and molecular features critical for drug-target interactions. GCNs provide deep insights into molecular interactions via relational data, whereas transformers increase prediction accuracy by capturing complex dependencies within biological sequences. Network-based models offer a systematic perspective by integrating diverse data sources, and traditional ML efficiently handles large datasets to improve overall predictive accuracy. Collectively, these AI-driven methods are transforming drug-target predictions and advancing the development of personalized therapy. This review summarizes the application of AI in drug development, particularly in drug-target prediction, and offers recommendations on models and algorithms for researchers engaged in biomedical research. It also provides typical cases to better illustrate how AI can further accelerate development in the fields of biomedicine and drug discovery.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
从药物-靶标相互作用的角度阐述人工智能在药物开发中的作用。
药物开发一直是生物医学领域的关键问题。随着人工智能(AI)等信息技术的飞速发展和大数据时代的到来,人工智能辅助药物开发已成为一种新的趋势,特别是在预测药物靶点关联方面。为了应对药物靶标预测的挑战,人工智能驱动的模型已经成为强大的工具,通过有效地从复杂的生物数据中提取特征,准确地模拟分子相互作用,并精确预测潜在的药物靶标结果,提供了创新的解决方案。传统的机器学习(ML)、基于网络和高级深度学习架构,如卷积神经网络(cnn)、图卷积网络(GCNs)和变压器,在其中发挥着关键作用。这篇综述系统地编译和评估了用于药物和药物组合靶标预测的人工智能算法,突出了它们的理论框架、优势和局限性。cnn有效地识别了药物-靶标相互作用的关键空间模式和分子特征。GCNs通过关系数据提供对分子相互作用的深入了解,而变压器通过捕获生物序列中的复杂依赖关系来提高预测准确性。基于网络的模型通过集成不同的数据源提供了一个系统的视角,传统的机器学习有效地处理大型数据集,以提高整体预测的准确性。总的来说,这些人工智能驱动的方法正在改变药物靶标预测,并推动个性化治疗的发展。本文综述了人工智能在药物开发特别是药物靶点预测方面的应用,并为从事生物医学研究的研究人员提供了模型和算法方面的建议。它还提供了典型案例,以更好地说明人工智能如何进一步加速生物医学和药物发现领域的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Astrocytes: Unveiling their role in the molecular mechanism of natural antidepressants. A novel proteolysis-targeting chimera strategy targeting multiple immune checkpoints containing ITIMs enhances antitumor immunity. Metabolic heterogeneity, networks, and biomarkers of drug-induced liver injury. Exploring TGFBR3 in disease pathogenesis: Mechanisms, clinical implications, and pharmacological modulation. Recent advances in the analysis of unsaturated fatty acids in biological samples based on chemical derivatization and mass spectrometry techniques.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1